EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Communicating dermatologic drug safety: a comparative evaluation of United States and United Kingdom pharmacovigilance systems using dapsone as a model medication

Sarah E Burstein, Howard Maibach

European Journal of Clinical Pharmacology · 2026-12 · 82 (12)

DOI: 10.1007/s00228-026-04231-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 21.11.2026. Verfasst von Sarah E Burstein und 1 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: East Carolina University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Postmarketing pharmacovigilance systems are essential for identifying adverse drug reactions (ADRs) that may not be recognized during premarketing clinical trials. Although the United States Food and Drug Administration (FDA) Adverse Event Monitoring System (AEMS) and the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme share the common objective of medication safety surveillance, little is known about how these systems differ in organizing and communicating postmarketing safety information to clinicians. This study compared the clinician-facing organization, accessibility, and communication of postmarketing safety information between the FDA AEMS Public Dashboard and the MHRA Yellow Card Interactive Drug Analysis Profile (iDAP) using dapsone as a representative dermatologic medication.

Methods

A cross-sectional comparative pharmacovigilance study was conducted using publicly available FDA AEMS and MHRA Yellow Card data extracted on June 29, 2026. Descriptive analyses characterized adverse-event reports, patient demographics, clinical outcomes, MedDRA Preferred Terms, and System Organ Class distributions. The two pharmacovigilance platforms were qualitatively compared using a predefined framework assessing data accessibility, organization, clinical usability, and research utility.

Results

The FDA AEMS identified 4,793 reports associated with dapsone-containing products, including 3,686 (76.9%) classified as serious and 280 (5.8%) reporting death. The MHRA Yellow Card Scheme identified 699 reports comprising 1,701 adverse reactions, including 559 (80.0%) serious reports and 25 (3.6%) fatal outcomes. Both systems demonstrated overlapping patterns of reported adverse reactions. Despite similar pharmacovigilance outputs, substantial differences were observed in the communication of safety information. The FDA emphasized downloadable datasets, customizable searches, and case-level transparency to facilitate secondary pharmacovigilance analyses, whereas the MHRA prioritized standardized, drug-specific summaries, hierarchical MedDRA organization, integrated visualizations, and contextual guidance to support rapid clinical interpretation.

Conclusions

The FDA AEMS and MHRA Yellow Card Scheme identify similar postmarketing safety profiles for dapsone while employing distinct approaches to communicating pharmacovigilance information. These complementary strengths suggest that future clinician-facing pharmacovigilance platforms should integrate the analytical flexibility of the FDA with the standardized, medication-specific communication strategies of the MHRA to improve the translation of postmarketing safety data into dermatology practice while preserving scientific transparency.

Förderung

  • East Carolina University

Zitieren

APA

Burstein, S. E., & Maibach, H. (2026). Communicating dermatologic drug safety: a comparative evaluation of United States and United Kingdom pharmacovigilance systems using dapsone as a model medication. European Journal of Clinical Pharmacology, 82(12). https://doi.org/10.1007/s00228-026-04231-3

Vancouver

Burstein SE, Maibach H. Communicating dermatologic drug safety: a comparative evaluation of United States and United Kingdom pharmacovigilance systems using dapsone as a model medication. European Journal of Clinical Pharmacology. 2026;82(12). doi:10.1007/s00228-026-04231-3

BibTeX
@article{Burstein2026,
  author = {Burstein, Sarah E and Maibach, Howard},
  title = {Communicating dermatologic drug safety: a comparative evaluation of United States and United Kingdom pharmacovigilance systems using dapsone as a model medication},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  volume = {82},
  number = {12},
  doi = {10.1007/s00228-026-04231-3}
}
Kostenlos starten →